IL17RB and urinary bladder carcinoma: The results of a complex study on the immunoreactivity of the ligands and receptors of the IL-17 family in patients with bladder cancer showed significantly elevated IL-17A, IL-17F, and IL-17RC immunoreactivity in the bladder cancer group but decreased IL-17E, IL-17RA, and IL-17RB immunoreactivity.